-transparent.png){kind=logo}
36 previously treated patients (25 with anthracyclines) with advanced epithelial ovarian cancer have been treated with intraperitoneal (i.p.) mitoxantrone (M) at increasing doses. The response was evaluated through repeated laparoscopy with multiple biopsies and serial measurement of Ovarian Cancer Antigen 125 (CA 125); 11/36 patients had a complete (6 patients) or partial (5 patients) response. Toxicity (both local and general) was observed starting from 25 mg/m2 of M per cycle. The amount of drug reaching systemic circulation was monitored by measuring M plasma value after i.p. treatment. This study showed wide variations in serum levels obtained after i.p. doses ranging from 23 to 36 mg/m2. The area under the curve (AUC) of mitoxantrone plasma samples, did not correlate with the i.p. administered dose. Conversely, a correlation seems to exist between the plasma AUC and the responder status. Patients who showed clinical responses to i.p. treatment with mitoxantrone had AUCs and plasma peak levels of the drug that were significantly higher than those in non-responders (P = 0.03, Fisher's exact test).
M O Nicoletto, and
R Padrini, and
E Ferrazzi, and
O Nascimben, and
E Visonà, and
S Tumolo, and
M Palumbo, and
L Costa, and
O Vinante, and
S Monfardini
April 1994,
Annals of oncology : official journal of the European Society for Medical Oncology,
M O Nicoletto, and
R Padrini, and
E Ferrazzi, and
O Nascimben, and
E Visonà, and
S Tumolo, and
M Palumbo, and
L Costa, and
O Vinante, and
S Monfardini
January 1990,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M O Nicoletto, and
R Padrini, and
E Ferrazzi, and
O Nascimben, and
E Visonà, and
S Tumolo, and
M Palumbo, and
L Costa, and
O Vinante, and
S Monfardini
June 1991,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M O Nicoletto, and
R Padrini, and
E Ferrazzi, and
O Nascimben, and
E Visonà, and
S Tumolo, and
M Palumbo, and
L Costa, and
O Vinante, and
S Monfardini
April 1999,
Gynecologic oncology,
M O Nicoletto, and
R Padrini, and
E Ferrazzi, and
O Nascimben, and
E Visonà, and
S Tumolo, and
M Palumbo, and
L Costa, and
O Vinante, and
S Monfardini
June 1994,
American journal of clinical oncology,
M O Nicoletto, and
R Padrini, and
E Ferrazzi, and
O Nascimben, and
E Visonà, and
S Tumolo, and
M Palumbo, and
L Costa, and
O Vinante, and
S Monfardini
January 2000,
Cancer chemotherapy and pharmacology,
M O Nicoletto, and
R Padrini, and
E Ferrazzi, and
O Nascimben, and
E Visonà, and
S Tumolo, and
M Palumbo, and
L Costa, and
O Vinante, and
S Monfardini
January 1991,
Annals of oncology : official journal of the European Society for Medical Oncology,
M O Nicoletto, and
R Padrini, and
E Ferrazzi, and
O Nascimben, and
E Visonà, and
S Tumolo, and
M Palumbo, and
L Costa, and
O Vinante, and
S Monfardini
June 1997,
American journal of clinical oncology,
M O Nicoletto, and
R Padrini, and
E Ferrazzi, and
O Nascimben, and
E Visonà, and
S Tumolo, and
M Palumbo, and
L Costa, and
O Vinante, and
S Monfardini
June 1987,
Cancer treatment reports,
M O Nicoletto, and
R Padrini, and
E Ferrazzi, and
O Nascimben, and
E Visonà, and
S Tumolo, and
M Palumbo, and
L Costa, and
O Vinante, and
S Monfardini
January 1987,
Progress in clinical and biological research,
